AI Article Synopsis

  • Current treatments for leishmaniasis have high toxicity and failure rates, highlighting the need for new, less toxic drugs.
  • A study tested several sulfonamide 4-methoxychalcone derivatives for their effectiveness against L. amazonensis and found that compound 3f showed the best results with low toxicity, while compound 3i was more effective against L. braziliensis.
  • Molecular modeling revealed that factors like molecular volume and electron density play a role in the effectiveness of these compounds, suggesting they could lead to new treatment options for leishmaniasis.

Article Abstract

Current drugs for treating leishmaniasis are still associated with significant toxicity and failure rates. Thus, new effective and less toxic antileishmanial agents are still in need. Herein, we tested a series of sulfonamide 4-methoxychalcone derivatives against L. amazonensis promastigote and amastigote forms to identify its antileishmanial profile against this species compared to L. braziliensis. In addition, we used molecular modeling tools to determine stereoelectronic features that may lead to the antileishmanial profile. Interestingly, all tested compounds were able to affect L. amazonensis promastigote form in a concentration-dependent manner and with low cytotoxicity, except for derivative 3g. However, our results showed that compound 3f (para-Cl) presents the best profile against both L. amazonensis forms (promastigote and amastigote), differently from that observed for L. braziliensis, when compound 3i was the most active. Structure-activity relationship (SAR) analysis of these derivatives pointed molecular volume, HOMO density, and conformational aspects as important characteristics for parasitic profile. Overall, sulfonamide 4-methoxychalcone derivatives may be pointed out not only as lead compounds for treating leishmaniasis (i.e., 3f) but also as experimental tools presenting parasite-selectivity (i.e., 3i).

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00284-009-9447-2DOI Listing

Publication Analysis

Top Keywords

sulfonamide 4-methoxychalcone
12
4-methoxychalcone derivatives
12
treating leishmaniasis
8
amazonensis promastigote
8
promastigote amastigote
8
antileishmanial profile
8
derivatives pointed
8
leishmania amazonensis
4
amazonensis growth
4
growth inhibitors
4

Similar Publications

Herein, we report the antimalarial activity of nine 4-methoxychalcone derivatives 1a-i and an initial analysis of their ADMET properties. All compounds showed potent activity against the P. falciparum chloroquine-resistant clone W2, with IC50 values ranging from 1.

View Article and Find Full Text PDF
Article Synopsis
  • Current treatments for leishmaniasis have high toxicity and failure rates, highlighting the need for new, less toxic drugs.
  • A study tested several sulfonamide 4-methoxychalcone derivatives for their effectiveness against L. amazonensis and found that compound 3f showed the best results with low toxicity, while compound 3i was more effective against L. braziliensis.
  • Molecular modeling revealed that factors like molecular volume and electron density play a role in the effectiveness of these compounds, suggesting they could lead to new treatment options for leishmaniasis.
View Article and Find Full Text PDF

Despite clinical importance of leishmaniasis, an infectious disease that affects 12 thousand million people in 88 countries, the treatment is still unsatisfactory due to its limited efficacy, cost expensive and undesirable side effects. Aiming to develop new antileishmanial lead compounds, we used a rational approach to synthesize a new set of sulfonamide 4-methoxychalcone derivatives (3a-3i) and evaluate the sulfonamide and methoxy moieties as promising adding-groups to chalcones. For that purpose we tested this new set against Leishmania braziliensis promastigotes and intracellular amastigotes and determined its cell toxicity profile.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!